protein tyrosine phosphatase non-receptor type 2Genealiases: PTN2 · PTPT · TC-PTP · TC45 · TC48 · TCELLPTP
Q-omics provides the consensus-scored PTPN2 profile across patient tissues and cancer cell-line models. PTPN2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PTPN2 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, PTPN2 protein abundance shows 22,375 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where PTPN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN2 survival associations across molecular data types. PTPN2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN2 RNA expression–survival associations across cancer types. High PTPN2 expression shows unfavorable associations in ACC, KIRC, LGG and KIRP, but favorable associations in SKCM and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PTPN2 RNA expression.
This table summarizes PTPN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN2 shows higher tumor expression in HNSC, BLCA, KIRC, STAD, CHOL and LIHC. The HNSC box plot shows higher PTPN2 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with PTPN2 in patient tissues and cancer cell lines. In patient samples, PTPN2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
